



Time Slot	Session	Description
9:00 a.m. – 9:30 a.m.	<i>Registration and Continental Breakfast</i>	
9:30 a.m. – 9:40 a.m.	<i>Opening Remarks</i> Scott Cunningham , Partner, Covington	
9:40 a.m. – 10:40 a.m.	Plenary Session One: <i>Life Sciences Dealmaking in 2025</i> <ul style="list-style-type: none"> ▪ Ingrid Rechtin, Moderator, Partner, Covington ▪ John Kollins, Chief Executive Officer and Corporate Director, Respira Therapeutics ▪ Grace Han McMahon, Associate Vice President and Head, Pacific BD&L, Merck ▪ Andrew Shediak, Healthcare Investment Banking Director, TD Cowen ▪ Amy Toro, Partner, Covington 	This panel will cover learning from recent life sciences corporate transactions, including licensing, collaborations, financings, and M&A. Topics to be addressed will include deal structuring, notable therapeutic areas and modalities, recommendations for execution, and trends to watch in the coming year.
10:40 a.m. – 10:50 a.m.	<i>Morning Break</i>	
10:50 a.m. – 11:50 a.m.	Plenary Session Two: <i>So You've Got Yourself a Promising Candidate – Planning Ahead for Commercialization</i> <ul style="list-style-type: none"> ▪ Alexa Hansen, Moderator, Partner, Covington ▪ Scott Cunningham, Partner, Covington ▪ Mark Kafka, Vice President, Intellectual Property & Transactions, Denali ▪ Philip LoScalzo, Chief Compliance Officer, ImmunityBio, Inc. 	Early stage clinical trials have gone well, and your promising drug candidate is moving into pivotal clinical testing. As you look forward to FDA approval, what are the things that you should be thinking about now to best position your company to go commercial? The panelists will explore regulatory, healthcare compliance, IP, business strategy, and other considerations to help you plan ahead for commercialization.
11:50 a.m. – 12:05 p.m.	<i>Buffet Lunch & Networking</i>	
12:05 p.m. – 12:50 p.m.	Luncheon Program A Fireside Chat with Eric Holder , Covington Senior Counsel and Former United States Attorney General	



Time Slot	Session	Description
	Featuring Matthew Shapanka , Covington Special Counsel	
12:50 p.m. – 1:10 p.m.	CovTalk Session: <i>Regulation in Flux: What Comes Next for Diagnostics?</i> <ul style="list-style-type: none"> Amy Leiser, Special Counsel, Covington 	For decades, FDA's approach to regulating diagnostics has been in flux, and another major shift could be coming. This CovTalk will explore the past, present, and—most importantly—the future of diagnostics regulation.
1:10 p.m. – 1:20 p.m.	<i>Afternoon Break</i>	
1:20 p.m. – 2:20 p.m.	Plenary Session Three: <i>As AI Collides with The Drug Life Cycle, What Changes and What Doesn't?</i> <ul style="list-style-type: none"> Joe Franklin, Moderator, Special Counsel, Covington Lisa Taylor Ash, Chief Operating Officer & General Counsel, Shape Therapeutics Inc. Einar Stole, Partner, Covington Tammy Tompkins, Chief Legal Officer, Insitro Lindsey Tonsager, Partner, Covington 	The increasing adoption of AI in all aspects of the life sciences can make it difficult to separate signal from noise. The panelists will explore AI use cases throughout the biopharma life cycle – from drug discovery and clinical development to the post-market – and discuss implications for IP, regulatory requirements, commercial transactions, and more.
2:20 p.m. – 2:30 p.m.	<i>Closing Remarks</i> Scott Cunningham , Partner, Covington	
2:30 p.m. – 3:30 p.m.	<i>Afternoon Reception</i>	